6/22/2020 4:16:06 PM
Leap Therapeutics Announces Closing Of Public Offering Of Common Stock
6/18/2020 9:06:05 AM
Leap Therapeutics Announces Pricing Of $45 Mln Of Common Stock And Pre-Funded Warrants
6/17/2020 4:03:03 PM
Leap Therapeutics Announces Proposed Public Offering Of Common Stock
3/18/2020 7:02:25 AM
Leap Therapeutics Announces Executive Leadership Changes; Christopher Mirabelli To Step Down As President And CEO
3/16/2020 7:18:16 AM
Leap Therapeutics Q4 Loss Per Share $0.33 Vs EPS $0.10 Prior Year
1/3/2020 8:56:50 AM
Leap Therapeutics, BeiGene Announce Exclusive Option & License Agreement For DKN-01
11/14/2019 7:12:44 AM
Leap Therapeutics Q3 Loss Per Share $0.33 Vs Loss $0.55 Prior Year
8/9/2019 7:13:50 AM
Leap Therapeutics Q2 Net Loss $8.4 Mln Vs $7.4 Mln Last Year
8/6/2019 7:41:30 AM
Leap Presents Positive Clinical Results For The Combination Of DKN-01 Plus Keytruda
7/11/2019 8:04:20 AM
Leap Therapeutics Announces Common Stock Purchase Agreements For Up To $21 Mln With Lincoln Park Capital
5/15/2019 7:47:03 AM
Leap Therapeutics Q1 Net Loss $8.6 Mln Vs Loss $10.6 Mln Last Year
4/1/2019 4:09:07 PM
Leap Therapeutics Q4 Net Income To Shareholders $1.48 Mln Vs. Loss $6.59 Mln Last Year
1/31/2019 4:33:35 PM
Leap Therapeutics Announces Proposed Public Offering Of Common Stock And Warrants